07:00 , Aug 10, 2009 |  BioCentury  |  Finance

Hope springs eternal

In a turn of events that could hardly have been imagined even a couple of months ago, some biotech bankers, VCs and companies are prepping for the return of an IPO market. The most optimistic anticipate...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Jun 23, 2003 |  BioCentury  |  Regulation

McClellan's brain trust

FDA's Activist McClellan's brain trust FDA Commissioner Mark McClellan has stocked his brain trust with economists, advocates of smarter regulation and individuals who understand biotech and finance. The American Enterprise Institute (AEI), a business-oriented think tank where...
08:00 , Feb 10, 2003 |  BioCentury  |  Finance

The sound of silence

The government's proposed overhaul of how Wall Street does business aims to erase the role of sellside analysts in the financing process, imposing new worries on a biotech sector already littered with microcap companies that...
08:00 , Jan 13, 2003 |  BioCentury  |  Finance

Europe's dilemma

Peering into 2003, European equity markets for biotech look muted, as the flight of institutional capital to the U.S. continues apace, and European biobanking scales back from its expansion binge during the retail-driven genomics bubble....
07:00 , Jun 10, 2002 |  BioCentury  |  Finance

Ebb & Flow

The biotech industry raised a record amount of money in the first quarter, $5.7 billion, the best start to any year for the industry with the exception of 2000, when biotech took in $13.1 billion...
07:00 , Jun 3, 2002 |  BC Extra  |  Financial News

Control Delivery trims IPO

Control Delivery Systems (Watertown, Mass.), a developer of sustained-release drug delivery products, reduced the price range in its proposed IPO, and now plans to sell $5.4 million shares at $12-$14. The company originally filed in...
07:00 , May 13, 2002 |  BioCentury  |  Finance

Ebb & Flow

A little more than two years after its hyped-up creation, a piece of the Franco-American venture ValiGen N.V. filed for bankruptcy protection last week, and the financial outlook for its other ventures remain uncertain. ValiGen SA,...
08:00 , Feb 19, 2002 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Incyte Genomics Inc. (INCY), Palo Alto, Calif. Business: Genomics Deutsche Banc Alex. Brown analyst Dennis Harp lowered his rating to "market perform" from "buy" and decreased his price target to $15. He also lowered his...
08:00 , Feb 11, 2002 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C. Business: Ophthalmic Deutsche Banc Alex. Brown analyst Dennis Harp lowered his 2002 and 2003 EPS estimates to $0.30 and $0.50 from $0.40 and $0.70, respectively. He said the revisions...